Polymyositis and dermatomyositis, New England Journal of Medicine, vol.292, issue.7, pp.344-347, 1975. ,
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscular Disorders, vol.14, issue.5, pp.337-345, 2003. ,
Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?, Journal of the American Academy of Dermatology, vol.46, issue.4, pp.626-636, 2002. ,
Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients, Journal of the European Academy of Dermatology and Venereology, vol.32, issue.7, pp.1164-1172, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01821363
Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis, Clinics, vol.68, issue.7, pp.909-914, 2013. ,
A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy, Clinical Reviews in Allergy & Immunology, vol.52, issue.1, pp.1-19, 2017. ,
Four dermatomyositis-specific autoantibodies-anti-TIF1?, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort, Autoimmunity Reviews, vol.13, issue.12, pp.1211-1219, 2014. ,
Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study, Archives of Dermatology, vol.147, issue.4, pp.391-398, 2011. ,
Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis, Journal of Dermatological Science, vol.84, issue.3, pp.272-281, 2016. ,
Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study, Arthritis Research & Therapy, vol.19, issue.1, p.259, 2017. ,
,
Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis, Arthritis & Rheumatism, vol.64, issue.2, pp.523-532, 2012. ,
Anti-TIF1-? antibody and cancer-associated myositis: a clinicohistopathologic study, Neurology, vol.87, issue.3, pp.299-308, 2016. ,
Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins, Arthritis & Rheumatism, vol.64, issue.2, pp.513-522, 2012. ,
Autoantibodies to a 140-kd polypeptide, CADM-140, Arthritis & Rheumatism, vol.52, issue.5, pp.1571-1576, 2005. ,
Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum, Arthritis Care and Research, vol.65, issue.8, pp.1307-1315, 2013. ,
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study, Journal of the American Academy of Dermatology, vol.65, issue.1, pp.25-34, 2011. ,
Anti-MDA5 and anti-TIF1-? antibodies have clinical significance for patients with dermatomyositis, Rheumatology, vol.49, issue.9, pp.1726-1733, 2010. ,
The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM, Rheumatology, vol.51, issue.7, pp.1278-1284, 2012. ,
Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies, The American Journal of the Medical Sciences, vol.355, issue.1, pp.48-53, 2018. ,
Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis, Arthritis Care & Research, vol.65, issue.8, pp.1316-1324, 2013. ,
Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis, BMC Musculoskeletal Disorders, vol.11, issue.1, p.223, 2010. ,
Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis, The British Journal of Dermatology, vol.176, issue.2, pp.395-402, 2017. ,
Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Rheumatology, vol.51, issue.9, pp.1563-1570, 2012. ,
American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative, Annals of the Rheumatic Diseases, vol.76, issue.5, pp.792-801, 2016. ,
Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease, Oncotarget, vol.8, issue.44, pp.76129-76140, 2017. ,
Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis, Arthritis Care & Research, vol.68, issue.5, pp.689-694, 2016. ,
Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis, The Journal of Dermatology, vol.45, issue.1, pp.46-52, 2018. ,
The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains, Journal of Biological Chemistry, vol.277, issue.23, pp.20611-20617, 2002. ,
Clinical and serological characterization of the anti-MJ antibody in childhood myositis, Arthritis & Rheumatism, vol.40, issue.9, p.139, 1997. ,
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis, Arthritis Research & Therapy, vol.14, issue.2, p.97, 2012. ,
Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy, Annals of the Rheumatic Diseases, vol.71, issue.5, pp.710-713, 2012. ,
Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options, Clinical and Experimental Rheumatology, vol.35, issue.2, pp.303-308, 2017. ,
Differential clinical associations of anti-nuclear matrix protein 2 autoantibodies in patients with idiopathic inflammatory myopathies, Arthritis & Rheumatology, vol.70, issue.8, pp.1288-1297, 2018. ,
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?, Arthritis & Rheumatism, vol.65, issue.11, pp.2954-2962, 2013. ,
Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis, Journal of Dermatological Science, vol.40, issue.3, pp.215-217, 2005. ,
Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients, The Journal of Dermatology, vol.38, issue.10, pp.973-979, 2011. ,
Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1621-1625, 2009. ,
Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort, Journal of Immunological Methods, vol.384, issue.1-2, pp.128-134, 2012. ,
Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort, Annals of the Rheumatic Diseases, vol.72, issue.1, pp.151-153, 2013. ,
Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients, Autoimmunity, vol.46, issue.4, pp.279-284, 2013. ,
Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts, Scientific Reports, vol.7, issue.1, p.188, 2017. ,
Autoantibodies in polymyositis, Rheumatic Diseases Clinics of North America, vol.18, issue.2, pp.455-482, 1992. ,
Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study, PLoS One, vol.10, issue.3, p.120313, 2015. ,
Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies, The Journal of Rheumatology, vol.44, issue.7, pp.1051-1057, 2017. ,
Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients, Annals of the Rheumatic Diseases, vol.73, issue.1, pp.227-232, 2014. ,
Interleukin-18 and IL-18 binding protein, Frontiers in Immunology, vol.4, p.289, 2013. ,
Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies, Clinical and Experimental Immunology, vol.146, issue.1, pp.21-31, 2006. ,
Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease, Rheumatology, vol.49, issue.10, pp.1878-1881, 2010. ,
Serum interleukin-18 level is associated with disease activity and interstitial lung disease in patients with dermatomyositis, Archives of Rheumatology, vol.32, issue.3, pp.181-188, 2017. ,
Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases, Cytokine, vol.60, issue.2, pp.334-337, 2012. ,
Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Clinical Rheumatology, vol.32, issue.3, pp.395-398, 2013. ,
Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease, Clinical Rheumatology, vol.35, issue.1, pp.117-125, 2016. ,
Interleukin 15: biology and relevance to human disease, Blood, vol.97, issue.1, pp.14-32, 2001. ,
Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity, Rheumatology International, vol.32, issue.3, pp.639-643, 2012. ,
Serum levels of interleukin 15 in patients with rheumatic diseases, The Journal of Rheumatology, vol.28, issue.11, pp.2389-2391, 2001. ,
Increased IL-15 production of muscle cells in polymyositis and dermatomyositis, International Immunology, vol.14, issue.8, pp.917-924, 2002. ,
Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor ? expression in muscle tissue of patients with polymyositis or dermatomyositis, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.1055-1063, 2012. ,
Interleukin-15: a novel anabolic cytokine for skeletal muscle, Endocrinology, vol.136, issue.8, pp.3669-3672, 1995. ,
Interleukin-17 increases the effects of IL-1? on muscle cells: arguments for the role of T cells in the pathogenesis of myositis, Journal of Neuroimmunology, vol.137, issue.1-2, pp.125-133, 2003. ,
Interleukin-17 and interleukin-23 in patients with polymyositis and 12 Journal of Immunology Research dermatomyositis, Scandinavian Journal of Rheumatology, vol.40, issue.3, pp.217-220, 2011. ,
IL-6: a new era for the treatment of autoimmune inflammatory diseases, pp.131-147, 2015. ,
Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease, vol.53, pp.2196-2203, 2014. ,
Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis, Arthritis & Rheumatism, vol.60, issue.11, pp.3436-3446, 2009. ,
Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis, Clinical and Developmental Immunology, vol.2013, 2013. ,
IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis, BioMed Research International, vol.2014, 2014. ,
Increased serum LIGHT levels correlate with disease progression and severity of interstitial pneumonia in patients with dermatomyositis: a case control study, PLoS One, vol.10, issue.10, p.140117, 2015. ,
Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course, Arthritis & Rheumatism, vol.64, issue.12, pp.4078-4086, 2012. ,
Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease, Modern Rheumatology, vol.24, issue.4, pp.633-636, 2014. ,
The immunobiology of interleukin-27, Annual Review of Immunology, vol.33, issue.1, pp.417-443, 2015. ,
Serum levels of interleukin-27 and interleukin-33 in patients with dermatomyositis and polymyositis compared to healthy control subjects, Gene, Cell and Tissue, vol.2, issue.4, p.31087, 2015. ,
IL-35 and autoimmunity: a comprehensive perspective, Clinical Reviews in Allergy & Immunology, vol.49, issue.3, pp.327-332, 2015. ,
Interleukin-35 in idiopathic inflammatory myopathies, Annals of the Rheumatic Diseases, vol.75, p.1109, 2016. ,
The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis, Clinical Rheumatology, vol.35, issue.11, pp.2715-2721, 2016. ,
Cytokines in idiopathic inflammatory myopathies: review, Autoimmunity, vol.39, issue.3, pp.177-190, 2006. ,
, BAFF, APRIL and their receptors: structure, function and signaling, vol.18, pp.263-275, 2006.
The function of BAFF on T helper cells in autoimmunity, Cytokine & Growth Factor Reviews, vol.25, issue.3, pp.301-305, 2014. ,
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.836-843, 2009. ,
B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis, Biomarkers in Medicine, vol.8, issue.3, pp.395-403, 2014. ,
BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies, The Journal of Rheumatology, vol.40, issue.3, pp.294-302, 2013. ,
The expression of BAFF in the muscles of patients with dermatomyositis, Journal of Neuroimmunology, vol.249, issue.1-2, pp.96-100, 2012. ,
HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis/dermatomyositis with interstitial lung disease, PLoS One, vol.11, issue.8, p.161436, 2016. ,
TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis, Annals of the Rheumatic Diseases, vol.72, issue.8, pp.1390-1399, 2013. ,
Dermatomyositis and type 1 interferons, Current Rheumatology Reports, vol.12, issue.3, pp.198-203, 2010. ,
Relationship between disease activity and type 1 interferon-and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis, Genes & Immunity, vol.13, issue.3, pp.207-213, 2012. ,
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis, Arthritis & Rheumatism, vol.56, issue.11, pp.3784-3792, 2007. ,
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis, Annals of Neurology, vol.57, issue.5, pp.664-678, 2005. ,
Molecular profiles of inflammatory myopathies, Neurology, vol.59, issue.8, pp.1170-1182, 2002. ,
Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases, PLoS One, vol.7, issue.1, p.29161, 2012. ,
Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies, Neurology, vol.76, issue.24, pp.2079-2088, 2011. ,
Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon ? in dermatomyositis, British Journal of Dermatology, vol.176, issue.5, pp.1224-1230, 2017. ,
Serum interferon-? is a useful biomarker in patients with anti-melanoma 13 Journal of Immunology Research differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis, Modern Rheumatology, vol.25, issue.1, pp.85-89, 2014. ,
Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease, British Journal of Dermatology, vol.167, issue.6, pp.1236-1244, 2012. ,
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases, Expert Review of Clinical Immunology, vol.10, issue.5, pp.593-619, 2014. ,
Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies, Mediators of Inflammation, vol.2014, p.10, 2014. ,
Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity, Arthritis Research & Therapy, vol.14, issue.2, p.48, 2012. ,
Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis, Respiratory Medicine, vol.109, issue.9, pp.1174-1180, 2015. ,
CXCL10 in psoriasis, Advances in Medical Sciences, vol.60, issue.2, pp.349-354, 2015. ,
Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study, Scientific Reports, vol.7, issue.1, p.1635, 2017. ,
A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis, Cytokine, vol.110, pp.226-231, 2018. ,
Type I interferon modulates monocyte recruitment and maturation in chronic inflammation, The American Journal of Pathology, vol.175, issue.5, pp.2023-2033, 2009. ,
Soluble CD163, Scandinavian Journal of Clinical and Laboratory Investigation, vol.72, issue.1, pp.1-13, 2011. ,
Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease, Arthritis Research & Therapy, vol.19, issue.1, p.9, 2017. ,
Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue, The Journal of Rheumatology, vol.42, issue.6, pp.979-987, 2015. ,
Increased serum levels of soluble CD163 in patients with scleroderma, Clinical Rheumatology, vol.31, issue.7, pp.1059-1064, 2012. ,
Association of serum soluble CD163 with polymyositis and dermatomyositis, especially in anti-MDA5 antibody-positive cases, The Journal of Rheumatology, vol.45, issue.7, pp.947-955, 2018. ,
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis, European Journal of Cancer, vol.59, pp.152-159, 2016. ,
Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis, The Journal of Rheumatology, vol.45, issue.6, pp.835-840, 2018. ,
Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil-lymphocyte ratios among various systemic autoimmune rheumatic diseases, APMIS, vol.125, issue.10, pp.863-871, 2017. ,
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: a retrospective observational study, PLoS One, vol.13, issue.1, p.190411, 2018. ,
Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis, Clinica Chimica Acta, vol.465, pp.11-16, 2017. ,
HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients, Clinical Rheumatology, vol.34, issue.4, pp.707-714, 2015. ,
Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis, Modern Rheumatology, vol.27, issue.1, pp.122-129, 2017. ,
Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: a retrospective case-control study, PLoS One, vol.13, issue.2, p.192491, 2018. ,
Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a korean retrospective cohort study, Journal of Korean Medical Science, vol.31, issue.3, pp.389-396, 2016. ,
Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis, European Journal of Dermatology, vol.12, issue.2, pp.165-169, 2002. ,
Corticosteroid resistant interstitial pneumonitis in dermatomyositis/-polymyositis: prediction and treatment with cyclosporine, The Journal of Rheumatology, vol.26, issue.7, pp.1527-1533, 1999. ,
Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan, The Journal of Rheumatology, vol.38, issue.8, pp.1636-1643, 2011. ,
Increased levels of HSPA5 in the serum of patients with inflammatory myopathies-preliminary findings, Clinical Rheumatology, vol.34, issue.4, pp.715-720, 2015. ,
Cardiac troponin testing in idiopathic inflammatory myopathies 14 Journal of Immunology Research and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity, Annals of the Rheumatic Diseases, vol.74, issue.5, pp.795-798, 2015. ,
Cardiac troponin and ?-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis, Clinica Chimica Acta, vol.306, issue.1-2, pp.27-33, 2001. ,
Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis, Rheumatology, vol.49, issue.7, pp.1354-1360, 2010. ,
Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis, Clinical Rheumatology, vol.35, issue.1, pp.113-116, 2016. ,
Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors, Modern Rheumatology, vol.26, issue.1, pp.115-120, 2016. ,
Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis, Rheumatology, vol.49, issue.9, pp.1713-1719, 2010. ,
Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases, Respiratory Investigation, vol.55, pp.130-137, 2017. ,
Clinical significance of von Willebrand factor in patients with adult dermatomyositis, Clinical Rheumatology, vol.24, issue.4, pp.352-357, 2005. ,
Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis, Modern Rheumatology, vol.23, issue.5, pp.872-883, 2013. ,
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease, Rheumatology, vol.41, issue.11, pp.1268-1272, 2002. ,
Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study, Internal Medicine Journal, vol.45, issue.6, pp.641-647, 2015. ,
KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis, Journal of Internal Medicine, vol.271, issue.6, pp.589-597, 2012. ,
Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis, Annals of the Rheumatic Diseases, vol.59, issue.4, pp.257-262, 2000. ,
Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study, Clinical Rheumatology, vol.35, issue.3, pp.663-666, 2016. ,
Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis, Clinical and Experimental Rheumatology, vol.26, issue.3, pp.414-420, 2008. ,
Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases, Modern Rheumatology, vol.23, issue.2, pp.345-350, 2013. ,
Relationship between cytomegalovirus reactivation and dermatomyositis, European Journal of Dermatology, vol.21, issue.2, pp.248-253, 2011. ,